arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Travere Therapeutics, Inc.

TVTX
$61.33 ▼ -1.12 (-1.79%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Travere Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.6B
Dividend Yield
Revenue Growth 55.6%
Op. Margin -29.0%
ROIC -37.3%
FCF / Share $-0.44
Trailing P/E
Price / Book 57.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$127.20M
↑ +55.6%
Net Income Profit after all expenses
$-37.10M
↑ +10.0%
Operating Margin Operating profit as % of sales
-29.0%
↓ -16.1% 13th
FCF / Share Free cash flow per share
$-0.44
↑ +8.0%
Long-Term Debt Long-term obligations
$46.00M
↓ -49.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
29
Returns
27
Financial Health
33
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 63 quarters